.png)
opra
Oncology Precision Project AArhus
About
The Oncology Precision Medicine Project Aarhus (OPRA) is a cutting-edge research initiative focused on advancing cancer treatment through the use of precision medicine.
The project, starting in 2017, uses advanced genomic sequencing and bioinformatics technologies to analyse tumor and blood samples and identify the specific genetic and molecular abnormalities that drive each patient's cancer.
By analysing these unique characteristics, the project aims to develop individualised treatment plans for each patient that target the underlying mechanisms of the disease, improving efficacy and minimising side effects.
The project is based at Aarhus University Hospital and involves collaboration between clinicians, researchers, and industry partners to accelerate the translation of precision medicine into clinical practice.
Contact
Britt Elmedal Laursen
Consultant (Oncology and Clinical Pharmacology), MD, PhD
Internationally Accredited Quality
The department is accredited by DANAK/ILAC by the international laboratory standard DS/EN ISO 15189:2013 for medical examination - genetics.
A complete method list of accredited analyses can be found at DANAK's website.
MOMA participates in several external quality assessment schemes: European Molecular Genetics Quality Networks (EMQN), Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) and Genomic Quality Assessment (GenQA).
.png)
People
Britt Elmedal Laursen
Consultant (Oncology and Clinical Pharmacology), MD, PhD
Christine Gaasdal Kassentoft
Clinical academic, MSc
Jesper Boulund Kristensen
Med. technologist, Health and safety rep.
